Download PDF

1. Company Snapshot

1.a. Company Description

Champions Oncology, Inc.develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.


The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis.


The company markets its products through internet, word of mouth, and sales force to patients and physicians.The company was formerly known as Champions Biotechnology, Inc.and changed its name to Champions Oncology, Inc.


in April 2011.Champions Oncology, Inc.was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Show Full description

1.b. Last Insights on CSBR

Champions Oncology's recent performance was driven by strong revenue growth, with Q2 2025 revenue increasing 17% to $13.5 million and Q3 2025 revenue expected to be reported after market close on March 11, 2025. The company's gross margin expanded to 45% in Q2, and adjusted EBITDA reached $1.1 million. Champions also enhanced its clinical bioanalytical services portfolio with new technology and leadership, and announced 17 abstracts accepted for presentation at the 2025 American Association for Cancer Research Annual Meeting. The company's operating efficiencies and growth strategy have positioned it for continued sales growth, with a 10% CAGR expected to 2026.

1.c. Company Highlights

2. Champions Oncology's Q2 FY2026 Earnings: A Mixed Bag

Champions Oncology reported revenue of $15 million, an 11% year-over-year increase, driven by stronger conversion of booked work due to a reduction in cancellations. Gross margin expanded to 52% from 45% last year, thanks to improved operational efficiencies. However, earnings per share (EPS) came in at $0.02, missing estimates of $0.08. Income from operations was $185,000, and adjusted EBITDA was approximately $800,000, with the company remaining on track to achieve full-year positive adjusted EBITDA.

Publication Date: Dec -20

📋 Highlights
  • Revenue Growth:: 11% YoY increase to $15 million, driven by reduced cancellations and higher conversion of booked work.
  • Adjusted EBITDA:: $800,000, with full-year positive guidance maintained despite $2 million rise in operating expenses.
  • Gross Margin Expansion:: 52% (vs. 45% last year) due to operational efficiencies, with potential for further growth as radiolabeling scales.
  • Operating Expenses:: $7 million (up $2 million YoY), reflecting strategic investments in data platform and Corellia's R&D.
  • Radiolabeling Demand:: Strengthened strategic focus, with customer demand validating its importance and driving in-house expansion plans.

Operational Highlights

The company's radiolabeling and radiopharmaceutical support workflows are a key highlight, with demand from customers reinforcing the strategic importance of this capability. Champions is also investing in its data platform, enhancing its functionality and expanding its utility for pharma partners. As CEO Robert Brainin noted, the company is focused on execution, maximizing conversion of existing bookings, and advancing capabilities to distinguish themselves in the market.

Investment in Growth Initiatives

Operating expenses were $7 million, up $2 million from last year, primarily due to investments in the data platform and Corellia's target discovery initiatives. The company expects some of these increases to be temporary. Corellia, the company's wholly owned subsidiary, is making progress in discussions with potential venture capital funding partners, with plans to redirect investment dollars toward accelerating growth in the data business once external funding is secured.

Outlook and Valuation

Champions believes it is well-positioned to deliver year-over-year revenue growth and positive adjusted EBITDA for the full fiscal year. Analysts estimate next year's revenue growth at 3.4%. With a P/S Ratio of 2.29 and an EV/EBITDA of 26.03, the market is pricing in a certain level of growth. The company's ROE of 57.5% and ROIC of 23.24% indicate a strong ability to generate returns on equity and invested capital. However, the P/E Ratio of 40.94 suggests that the stock may be trading at a premium.

3. NewsRoom

Card image cap

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

Dec -15

Source: seekingalpha.com

Card image cap

Market Today: Ford axes Lightning, iRobot bankrupt, Nvidia-China chips

Dec -15

Source: gurufocus.com

Card image cap

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Dec -15

Source: accessnewswire.com

Card image cap

First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi

Dec -15

Source: gurufocus.com

Card image cap

Dow Settles Lower But Records Weekly Gain: Investor Sentiment Declines, Greed Index Moves To 'Fear' Zone

Dec -15

Source: feeds.benzinga.com

Card image cap

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025

Dec -08

Source: accessnewswire.com

Card image cap

Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript

Sep -15

Source: seekingalpha.com

Card image cap

CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million

Sep -15

Source: accessnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.00%)

6. Segments

Pharmacology Services

Expected Growth: 3%

Champions Oncology's Pharmacology Services growth is driven by increasing demand for personalized medicine, advancements in precision oncology, and rising adoption of biomarker-based drug development. Additionally, growing need for targeted therapies, expanding oncology pipeline, and strategic partnerships are contributing to the segment's growth.

Other Translational Oncology Solutions

Expected Growth: 3%

Champions Oncology's Other Translational Oncology Solutions segment growth is driven by increasing adoption of personalized medicine, rising demand for biomarker-based cancer diagnostics, and strategic partnerships with pharmaceutical companies to accelerate drug development. Additionally, advancements in immuno-oncology and targeted therapies are fueling growth in this segment.

Personalized Oncology Services

Expected Growth: 3%

Champions Oncology's Personalized Oncology Services growth is driven by increasing demand for precision medicine, advancements in genomics and immunotherapy, and a growing need for personalized treatment options. Additionally, the company's unique tumorgraft platform and comprehensive biomarker testing capabilities position it for continued growth.

7. Detailed Products

TumorGraft

A platform that develops and banks patient-derived xenograft (PDX) models from various types of cancer, allowing for personalized cancer treatment and research

AngioPred

A predictive analytics platform that uses artificial intelligence and machine learning to identify biomarkers for angiogenesis, a key factor in cancer progression

Champions TumorGraft Platform

A comprehensive platform that provides a suite of services, including PDX model development, biomarker discovery, and personalized medicine solutions

Personalized Oncology Solutions

A range of services that provide personalized cancer treatment plans, including biomarker analysis, genomic profiling, and PDX modeling

8. Champions Oncology, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Champions Oncology, Inc. has a moderate threat of substitutes due to the availability of alternative cancer treatment options, but the company's unique approach to personalized oncology and its strong research and development capabilities mitigate this threat.

Bargaining Power Of Customers

Champions Oncology, Inc. has a low bargaining power of customers due to the specialized nature of its services and the lack of alternative providers, giving the company significant pricing power.

Bargaining Power Of Suppliers

Champions Oncology, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for its research and development activities, but the company's reliance on a few key suppliers for certain materials and services limits its negotiating power.

Threat Of New Entrants

Champions Oncology, Inc. has a low threat of new entrants due to the high barriers to entry in the personalized oncology market, including the need for significant research and development investments and regulatory approvals.

Intensity Of Rivalry

Champions Oncology, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry, but the company's unique approach and strong research and development capabilities help it to differentiate itself from competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 64.97%
Debt Cost 3.95%
Equity Weight 35.03%
Equity Cost 5.92%
WACC 4.64%
Leverage 185.48%

11. Quality Control: Champions Oncology, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Dianthus Therapeutics

A-Score: 4.8/10

Value: 6.7

Growth: 6.0

Quality: 5.0

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Tarsus Pharmaceuticals

A-Score: 4.5/10

Value: 6.2

Growth: 3.2

Quality: 4.1

Yield: 0.0

Momentum: 10.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Champions Oncology

A-Score: 4.5/10

Value: 2.2

Growth: 7.0

Quality: 5.9

Yield: 0.0

Momentum: 10.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Kymera Therapeutics

A-Score: 4.1/10

Value: 6.2

Growth: 3.1

Quality: 5.1

Yield: 0.0

Momentum: 8.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Oncternal Therapeutics

A-Score: 3.8/10

Value: 9.0

Growth: 4.3

Quality: 3.3

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
TScan Therapeutics

A-Score: 2.9/10

Value: 8.2

Growth: 4.2

Quality: 4.4

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.04$

Current Price

6.04$

Potential

-0.00%

Expected Cash-Flows